William Roberts, M.D. | Rady Children's ...

Dr. William D. Roberts

Claim this profile

Rady Children's Hospital - San Diego

Expert in Cancer
Expert in Neuroblastoma
51 reported clinical trials
108 drugs studied

About William D. Roberts

Education:

  • Graduated with an MD from Brown University School of Medicine.

Experience:

  • Chief of Hematology/Oncology, UC San Diego Department of Pediatrics.
  • Founded and directed the UC San Diego/Rady Children's Pediatric Hematology/Oncology Fellowship Program (2007-2015).
  • Vice President and Medical Director at Rady Children's Specialists San Diego medical group.
  • Principal investigator, UC San Diego/Rady Children's Children's Oncology Group Program.
  • Awarded the Rady Children's Excellence in Clinical Care Award in 2015.

Area of expertise

1

Cancer

Global Leader

William D. Roberts has run 14 trials for Cancer. Some of their research focus areas include:

Stage I
Stage IV
Stage II
2

Neuroblastoma

Global Leader

William D. Roberts has run 11 trials for Neuroblastoma. Some of their research focus areas include:

MYC positive
Stage IV
MYC negative

Affiliated Hospitals

Image of trial facility.

Rady Children's Hospital - San Diego

Image of trial facility.

Rady Children's Hospital

Clinical Trials William D. Roberts is currently running

Image of trial facility.

Selumetinib vs. Chemotherapy

for Brain Cancer

This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.

Recruiting

2 awards

Phase 3

Image of trial facility.

Inotuzumab Ozogamicin

for Acute Lymphoblastic Leukemia

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.

Recruiting

2 awards

Phase 3

More about William D. Roberts

Clinical Trial Related

8 years of experience running clinical trials · Led 51 trials as a Principal Investigator · 24 Active Clinical Trials

Treatments William D. Roberts has experience with

  • Cyclophosphamide
  • Radiation Therapy
  • Etoposide
  • Doxorubicin Hydrochloride
  • Vincristine Sulfate
  • Methotrexate

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does William D. Roberts specialize in?

Is William D. Roberts currently recruiting for clinical trials?

Are there any treatments that William D. Roberts has studied deeply?

What is the best way to schedule an appointment with William D. Roberts?

What is the office address of William D. Roberts?

Is there any support for travel costs?